SAGE Therapeutics' Refractory Status Epilepticus Program Demonstrates Efficacy in First-in-Man Experience; Case Study to be Highlighted at International SE Meeting
4/4/2013 11:51:43 AM
More...
|
SAGE Therapeutics Appoints Chief Scientific Officer, Strengthens Management Team
11/30/2011 10:12:53 AM
More...
|
Third Rock Ventures Launches SAGE Therapeutics with $35 Million Backing
10/18/2011 7:28:30 AM
More...
|